68.05
0.79 (1.17%)
| Previous Close | 67.26 |
| Open | 67.54 |
| Volume | 128,941 |
| Avg. Volume (3M) | 458,601 |
| Market Cap | 3,349,026,560 |
| Price / Earnings (TTM) | 15.97 |
| Price / Earnings (Forward) | 14.33 |
| Price / Sales | 2.90 |
| Price / Book | 1.72 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Profit Margin | 18.86% |
| Operating Margin (TTM) | 34.03% |
| Diluted EPS (TTM) | 4.29 |
| Quarterly Revenue Growth (YOY) | 7.10% |
| Quarterly Earnings Growth (YOY) | 1.40% |
| Total Debt/Equity (MRQ) | 56.91% |
| Current Ratio (MRQ) | 4.20 |
| Operating Cash Flow (TTM) | 251.52 M |
| Levered Free Cash Flow (TTM) | 188.69 M |
| Return on Assets (TTM) | 6.50% |
| Return on Equity (TTM) | 12.30% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bullish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bullish | Mixed | |
| Stock | Prestige Consumer Healthcare In | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.5 |
| Insider Activity | NA |
| Price Volatility | 4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 1.88 |
|
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige’s key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer’s Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Core |
| % Held by Insiders | 1.23% |
| % Held by Institutions | 108.15% |
| 52 Weeks Range | ||
| Median | 100.00 (46.95%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Canaccord Genuity | 08 Aug 2025 | 100.00 (46.95%) | Buy | 65.58 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 04 Sep 2025 | Announcement | Prestige Consumer Healthcare to Present at the Barclays Global Consumer Staples Conference |
| 07 Aug 2025 | Announcement | Prestige Consumer Healthcare Inc. Reports Fiscal 2026 First Quarter Results |
| 15 Jul 2025 | Announcement | Prestige Consumer Healthcare to Release Fiscal 2026 First Quarter Earnings Results |
| 17 Jun 2025 | Announcement | Medtech Products Inc. Issues Nationwide Recall of Little Remedies® Honey Cough Syrup Due to Microbial Contamination |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |